N
Newbang Biotechnology
Innovative dietary supplement raw material development
About Newbang Biotechnology
Nanjing Newbang Biotechnology (NNB) is a biotechnology company that develops and manufactures novel raw materials for the dietary supplement industry. The company was founded by Qilin Liao, who serves as the chairman and was recognized as one of the '10 Most Influential Business Leaders of 2022' by CIO Business Review.
Read full description
NNB operates with a focus on scientific research and innovation, supported by a 3,000-square-meter R&D laboratory designated as the Nanjing Engineering Technology Research Center in 2021. The firm's global team consists of over 100 scientists from more than 10 countries who have designed and delivered 100 unique raw materials. Newbang's business model involves providing high-quality ingredients to well-known brands and offering technical support for innovators in the health and nutrition space. The company serves a global market, with business operations spanning multiple countries.
The company's intellectual property portfolio is extensive, with 79 invention patents pending, including 31 PCT applications, and 9 granted invention patents across China, the United States, and Australia. It has also registered 99 trademarks domestically and internationally. Newbang has earned several qualifications, such as 'National High-tech Enterprise' and 'Jiangsu Province Specialized, Refined, and New Little Giant Enterprise'.
At a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Nanjing City, China
- Open positions
- None listed
- Dealroom signal
- 17.0/100
- Industry
- Health, Food
- Sector
- Food
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Latest news
Press, funding announcements and product moves mentioning Newbang Biotechnology.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Jul 2026 | $28M | $110M | China Life Private Equity Investment · Moxie Capital. · Mori Capital | ↗ |
| SERIES B✓Equity / VC | Feb 2026 | $0 | — | Addor Capital · Alan Asset Management · Wuhan Optics Valley Industrial Investment | ↗ |
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
- MCMingxi Capital
Addor Capital
Alan Asset Management- WIWuhan Optics Valley Industrial Investment
Series B and later3 investors entered at this stage
- CIChina Life Private Equity Investment
Moxie Capital.- MCMori Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Newbang Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Newbang Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.